Estónsko - estónčina - Ravimiamet

guerbet - gadoteerhape - süstelahus süstlis - 0,5mmol 1ml 20ml 10tk; 0,5mmol 1ml 15ml 1tk; 0,5mmol 1ml 15ml 10tk; 0,5mmol 1ml 20ml 1tk

Estónsko - estónčina - Ravimiamet

guerbet - gadoteerhape - süstelahus - 0,5mmol 1ml 15ml 1tk; 0,5mmol 1ml 20ml 1tk; 0,5mmol 1ml 60ml 1tk; 0,5mmol 1ml 5ml 1tk

Estónsko - estónčina - Ravimiamet

agfa healthcare imaging agents gmbh - gadoteerhape - süstelahus - 279,32mg 1ml 5ml 1tk; 279,32mg 1ml 10ml 10tk; 279,32mg 1ml 60ml 10tk; 279,32mg 1ml 15ml 1tk; 279,32mg 1ml 20ml 10tk; 279,32mg 1ml 60ml 1tk

Estónsko - estónčina - Ravimiamet

bracco imaging s.p.a. - gadoteridool - süstelahus - 0,5mmol 1ml 15ml 1tk; 0,5mmol 1ml 5ml 1tk; 0,5mmol 1ml 50ml 1tk

Estónsko - estónčina - Ravimiamet

bioveta a.s. - inaktiveeritud mikrosporoosi vaktsiin - süstesuspensioon - 500000cfu 1annus 10tk

Estónsko - estónčina - Ravimiamet

guerbet - gadoteerhape - süstelahus - 0,5mmol 1ml 60ml 1tk

Estónsko - estónčina - Ravimiamet

octapharma (ip) - humaanfibrinogeen - süste-/infusioonilahuse pulber ja lahusti - 1g 1tk

Estónsko - estónčina - Ravimiamet

farmak international sp. z o.o. - gadoteerhape - süstelahus - 0,5mmol 1ml 60ml 10tk; 0,5mmol 1ml 100ml 1tk; 0,5mmol 1ml 5ml 10tk; 0,5mmol 1ml 10ml 1tk; 0,5mmol 1ml 15ml 1tk; 0,5mmol 1ml 20ml 1tk; 0,5mmol 1ml 100ml 10tk; 0,5mmol 1ml 15ml 10tk; 0,5mmol 1ml 10ml 10tk

Európska únia - estónčina - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Európska únia - estónčina - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratoorsed süntsüütilised viirusinfektsioonid - vaktsiinid - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.